Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
eNq1mF1v2jAUhu/5FVHuSfhoB50C1cbKhtSqjII27aYyyaGYBTs9tvnYr59DQKOTo7YGX8Z23nPi8/rxUaLrzTL1VoCCctbx60HN94DFPKHsqeNPxv1q27/uVqIFWZGjZa2gFtQbvhenRIiOn88GUyBMBD/vbr+Afh/Q71a8iE8XEMsX65SkafCNiPkdyfI1XrTiNPGWIOc86fiZkrtRLxISdRbdNcffIiMxROF+5Hh28XhxPB6FudgbVJUAvCXsySgKzEozVojAZI9IeOK4Lcm3aaVNxQgEVxjDkMj5EPmKJpAYQ8xIKsAqyGydPACuUpB5EKN4uIiXwkqcLMhmBM8Dc9Kf9GxPbmS1Vq23Wo1ms3XRrrWabatQeLRV5irojwjjx3a72biqhcBCJAw2xLIyQ46SpI5qQkXvpa0cxUF4frX2CRVZSrbBQmS2W0WQ6GlAffjdfUj+BWNdUpHqPftPn6k0Dd+Z9WQPC0cZ5yzqccVkCTP6I9uN6HEmYVNeUTvMyc3eixTE+WT/cGZG/FBNUxrbAk0jR4GQk9GgnGfnQ8FnImCC7ljwg7KEr8X5GXNcU0fZZztMGkUzTOqPjav2h/rlpfUR+qUNVHK73CjkGYSaPlScApUBm/FTcaI9aZY6OPJMZtx1ODwmKZT0OFVLrmgXHloyZz53d4aKCaPo15uxrTm+K8Dtw+7RKE2TzqGsdsx1AXLtxNK83+/r4ng7aX4VmrExlzITH8NwTkRVEL1DwQzPDPSjG9Rd0+3kmi7algKKjlKfFrfd22tje7xeu8RPbUz37+8bYGMMiQpOqENBYme8HNycH8H/ulJnaQ9fMMNdmF0HSSTlzFVvo6ZGxZOgr8vK+qjZcD+b0ZL/H6W2jMLi30u3EoX5f5du5S9CI968
Q0ZpCSMHE2G8UDKT
